Lyell Immunopharma (LYEL) Financial Statements & Analysis

Lyell Immunopharma (LYEL) Income Statement

Lyell Immunopharma reported revenue of $36.00K in fiscal 2025 (fiscal year ended Dec 31, 2025), down 41.0% from $61.00K a year earlier. Lyell Immunopharma posted a net loss of $274.45M, compared with a net loss of $342.99M a year earlier. Gross margin was 100.0% and operating margin -748344.4%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $4.00K, down 50.0% from the same quarter a year earlier.

Lyell Immunopharma Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Lyell Immunopharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Revenue & Gross Profit
Revenue	0.04	0.06	0.13	84.68	10.65	7.76	0.66
Cost of Revenue	11.54	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.04	0.06	0.13	84.68	10.65	7.76	0.66
Operating Expenses
Research & Development	158.68	171.60	182.95	159.19	138.69	182.24	63.60
Selling, General & Administrative	45.14	52.04	66.98	117.31	89.06	46.88	39.15
Operating Expenses	269.44	358.82	247.14	271.74	225.43	219.69	102.75
Operating Income	-269.40	-358.76	-247.01	-187.06	-214.78	-211.94	-102.09
Other Income/Expense
Interest Income	13.08	24.07	23.45	7.05	1.17	5.94	8.12
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	-5.04	15.76	12.38	3.94	-36.61	7.47	-27.29
Income
Income Before Tax	-274.45	-342.99	-234.63	-183.12	-250.22	-204.47	-129.38
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-274.45	-342.99	-234.63	-183.12	-250.22	-204.47	-129.38
Net Income - Continuous Operations	-274.45	-342.99	-234.63	-183.12	-250.22	-204.47	-129.38
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-186.75	-199.30	-225.25	-168.94	-201.15	-215.43	-100.83
EBIT	-198.29	-218.93	-245.50	-186.96	-214.78	-219.72	-
Depreciation & Amortization	11.54	19.63	20.25	18.02	13.62	4.29	1.26
Earnings Per Share
Basic EPS	-16.00	-26.00	-19.00	-15.00	-37.00	-1.00	-1.00
Diluted EPS	-16.00	-26.00	-19.00	-15.00	-37.00	-1.00	-1.00
Basic Shares Outstanding	17.09	13.07	12.55	12.35	6.80	12.33	12.33
Diluted Shares Outstanding	17.09	13.07	12.55	12.35	6.80	12.33	12.33

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Lyell Immunopharma Financial Statements

What was Lyell Immunopharma's revenue in fiscal 2025?

Lyell Immunopharma reported revenue of $36.00K in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 41.0% from $61.00K a year earlier.

Is Lyell Immunopharma profitable?

No. Lyell Immunopharma reported a net loss of $274.45M in fiscal 2025. In fiscal 2024 it lost $342.99M.

What is Lyell Immunopharma's operating margin?

Lyell Immunopharma's operating income was −$269.40M on revenue of $36.00K in fiscal 2025, an operating margin of -748344.4%, compared with -588123.0% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition